Pharmexcil proposes collaboration with India-Japan Pharma Alliance in Japan.

With a view to represent the demands of the Indian pharma companies in Japan, the Pharmaceutical Export Promotion Council of India (Pharmexcil), is currently under discussion with India-Japan Pharma Alliance (IJPA) to enter into a Memorandum of Understanding (MoU) with them in Japan. Through this alliance, Pharmexcil hopes to get IJPA's assistance in getting appropriate inputs on regulatory requirements and market dynamics in Japan.

IJPA is an established alliance in Japan and as of today has no direct relationship with Pharmexcil. However, Dr Kailash D Sharma, one of the founding promoters and chairman of IJPA, and president and representative director, Zydus Pharma Japan informed that the association is currently in talks with Pharmexcil on a possible MoU between the two alliances, details of which will be discussed and agreed upon in the near future.

This strategic decision highlights the governments initiatives in strengthening its business relation with respect to pharmaceutical segment in Japan. The decision to collaborate with this IJPA was taken after the completion of the CPhI Japan in which Pharmexcil through its India pavilion had successfully represented 'brand India' in the Japanese market.

Pharmexcil stated that IJPA had helped the Council in organising Brand India Pharma campaign successfully in the sidelines of CPhI Japan, held recently.

According to Dr P V Appaji, director general (DG), Pharmexcil, “With respect to exports, Japan has a huge potential for growth in the generic segment that will provide an excellent business opportunity for the Indian generic pharma companies. Thus it is imperative that we strengthen this relation which is mutually beneficial for both the countries by providing a platform that will help us in understanding industry dynamics of Japan, so that we can take requisite steps to help and guide Indian companies in doing their business in the country.”

Further Dr Sharma informed that IJPA has been promoted with a view to understand the evolving Japanese government policy towards the generic medicines and to forge a closer bilateral ties between Indian and the Japanese companies in the pharma and other related business.

With the finalisation of the MoU, IJPA will be given the authority to act as the representative of Pharmexcil in Japan, through which Pharmexcil will be able to gauge and analyse the Japanese market more closely so that they will be able to address the issues and the challenges of the Indian companies that are based in Japan more aptly.

The collaboration will help Pharmexcil in getting a clear market dynamics that is prevalent in Japan so that through this they will be able to give important regulatory guidance to the Indian companies interested in establishing business in Japan and to help them overcome their challenges in doing so.

Dr Appaji informed that to further boost the trade between the two countries Pharmexcil is already in discussions with the Japanese generic associations to explore business opportunities with them in Japan. He stressed that this will be a very  important partnership as it will also act as a catalyst to many other collaborations between the two countries with respect to trade and commerce.

Taking ahead from CPhI Japan, Pharmexcil has again teamed up with CPhI  by participating and having a India Pavilion at CPhI South East Asia (SEA), in Indonesia from May 10 to 12 this year. CPhI SEA is being organised for the first time by the organisers and is being held in Jakarta.

Source : pharmabiz.com